Saturday, December 7: From Lab to Clinic: New Technologies and Therapies to Improve the Prevention and Treatment of VTE
Webcasts at the bottom
Guy Young, Anthonie WA. Lensing, Paul Monagle, MBBS, Christoph Male, et al.
CONCLUSIONS Treatment of children with bodyweight-adjusted rivaroxaban regimens resulted in exposures similar to those previously observed in adults receiving 20 mg once daily dosing and the level of exposure was not related to the efficacy, bleeding, or adverse events. Based on this analysis and in conjunction with the previously demonstrated similar efficacy and safety of rivaroxaban compared with standard anticoagulation, we conclude that the bodyweight-adjusted pediatric rivaroxaban regimens with either tablets or suspension are validated and provide a new alternative treatment option for VTE in children.
Yongzhi Qiu, Yumiko Sakurai, and Wilbur A. Lam
CONCLUSIONS We have, for the first time, developed a perfusable vascularized thrombus resolution assay that enables the tracking of inflammatory thrombi over weeks and is ideal for studying antithrombotic drugs effects and how they may restore microvascular barrier function. Studies assessing the formation of microvascular emboli in this context are ongoing.